Strategies and treatment alternatives in the management of Erdheim–Chester disease

Bibliography

• Volpicelli ER, Doyle L, Annes JP, et al. Erdheim-Chester disease presenting with cutaneous involvement: a case report and literature review. J Cutan Pathol 2011;38(3):280-5
   PubMedGoogle Scholar
• Haroche J, Arnaud L, Amoura Z. Erdheim-Chester disease. Curr Opin Rheumatol 2012;24(1):53-9
   PubMed Web of Science ®Google Scholar
• Arnaud L, Hervier B, Neel A, et al. CNS involvement and treatment with interferon-alpha are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients. Blood 2011;117(10):2778-82
   PubMed Web of Science ®Google Scholar
• Braiteh F, Boxrud C, Esmaeli B, Kurzrock R. Successful treatment of Erdheim-Chester disease, a non-Langerhans-cell histiocytosis, with interferon-alpha. Blood 2005;106(9):2992-4
   PubMed Web of Science ®Google Scholar
• Haroche J, Amoura Z, Trad SG, et al. Variability in the efficacy of interferon-alpha in Erdheim-Chester disease by patient and site of involvement: results in eight patients. Arthritis Rheum 2006;54(10):3330-6
   PubMed Web of Science ®Google Scholar
• Veyssier-Belot C, Cacoub P, Caparros-Lefebvre D, et al. Erdheim-Chester disease. Clinical and radiologic characteristics of 59 cases. Medicine 1996;75(3):157-69
   PubMed Web of Science ®Google Scholar
• Jendro MC, Zeidler H, Rosenthal H, et al. Improvement of Erdheim-Chester disease in two patients by sequential treatment with vinblastine and mycophenolate mofetil. Clin Rheumatol 2004;23(1):52-6
   PubMedGoogle Scholar
• Broccoli A, Stefoni V, Faccioli L, et al. Bilateral orbital Erdheim-Chester disease treated with 12 weekly administrations of VNCOP-B chemotherapy: a case report and a review of literature. Rheumatol Int 2012;32(7):2209-13
   PubMedGoogle Scholar
• Myra C, Sloper L, Tighe PJ, et al. Treatment of Erdheim-Chester disease with cladribine: a rational approach. Br J Ophthalmol 2004;88(6):844-7
   PubMed Web of Science ®Google Scholar
• Adam Z, Szturz P, Pour L, et al. Cladribine is highly effective in the treatment of Langerhans cell histiocytosis and rare histiocytic disorders of the juvenile xanthogranuloma group. Vnitr Lek 2012;58(6):455-65
   PubMedGoogle Scholar
• Adam Z, Sprlakova A, Rehak Z, et al. Partial regression of CNS lesions of Erdheim-Chester disease after treatment with 2-chlorodeoxadenosine and their full remission following treatment with lenalidomide. Klin Onkol 2011;24(5):367-81
   PubMedGoogle Scholar
• Adam Z, Koukalova R, Sprlakova A, et al. Successful treatment of Erdheim-Chester disease by 2-chlorodeoxyadenosine-based chemotherapy. Two case studies and a literature review. Vnitr Lek 2011;57(6):576-89
   PubMedGoogle Scholar
• Sheidow TG, Nicolle DA, Heathcote JG. Erdheim-Chester disease: two cases of orbital involvement. Eye (Lond) 2000;14(Pt 4):606-12
   PubMedGoogle Scholar
• Srikulmontree T, Massey HD, Roberts WN. Treatment of skeletal Erdheim-Chester disease with zoledronic acid: case report and proposed mechanisms of action. Rheumatol Int 2007;27(3):303-7
   PubMedGoogle Scholar
• Eyigor S, Kirazli Y, Memis A, Basdemir G. Erdheim-Chester disease: the effect of bisphosphonate treatment–a case report. Arch Phys Med Rehabil 2005;86(5):1053-7
   PubMedGoogle Scholar
• Mossetti G, Rendina D, Numis FG, et al. Biochemical markers of bone turnover, serum levels of interleukin-6/interleukin-6 soluble receptor and bisphosphonate treatment in Erdheim-Chester disease. Clin Exp Rheumatol 2003;21(2):232-6
   PubMed Web of Science ®Google Scholar
• Wimpissinger TF, Schernthaner G, Feichtinger H, Stackl W. Compression of kidneys in Erdheim-Chester disease of retroperitoneum: open surgical approach. Urology 2005;65(4):798
   PubMedGoogle Scholar
• Boissel N, Wechsler B, Leblond V. Treatment of refractory Erdheim-Chester disease with double autologous hematopoietic stem-cell transplantation. Ann Intern Med 2001;135(9):844-5
   PubMedGoogle Scholar
• Haroche J, Amoura Z, Charlotte F, et al. Imatinib mesylate for platelet-derived growth factor receptor-beta-positive Erdheim-Chester histiocytosis. Blood 2008;111(11):5413-15
   PubMedGoogle Scholar
• Janku F, Amin HM, Yang D, et al. Response of histiocytoses to imatinib mesylate: fire to ashes. J Clin Oncol 2010;28(31):e633-6
   Google Scholar
• Arnaud L, Pierre I, Beigelman-Aubry C, et al. Pulmonary involvement in Erdheim-Chester disease: a single-center study of thirty-four patients and a review of the literature. Arthritis Rheum 2010;62(11):3504-12
   PubMed Web of Science ®Google Scholar
• Aouba A, Georgin-Lavialle S, Pagnoux C, et al. Rationale and efficacy of interleukin-1 targeting in Erdheim-Chester disease. Blood 2010;116(20):4070-6
   PubMed Web of Science ®Google Scholar
• Tran TA, Pariente D, Lecron JC, et al. Treatment of pediatric Erdheim-Chester disease with interleukin-1-targeting drugs. Arthritis Rheum 2011;63(12):4031-2
   PubMedGoogle Scholar
• Aubert O, Aouba A, Deshayes S, et al. Favorable radiological outcome of skeletal Erdheim-Chester disease involvement with anakinra. Joint Bone Spine 2013;80(2):206-7
   PubMedGoogle Scholar
• Adam Z, Szturz P, Buckova P, et al. Interleukin-1 receptor blockade with anakinra provided cessation of fatigue, reduction in inflammation markers and regression of retroperitoneal fibrosis in a patient with Erdheim-Chester disease - case study and a review of literature. Vnitr Lek 2012;58(4):313-18
   PubMedGoogle Scholar
• Arnaud L, Gorochov G, Charlotte F, et al. Systemic perturbation of cytokine and chemokine networks in Erdheim-Chester disease: a single-center series of 37 patients. Blood 2011;117(10):2783-90
   PubMed Web of Science ®Google Scholar
• Dagna L, Girlanda S, Langheim S, et al. Erdheim-Chester disease: report on a case and new insights on its immunopathogenesis. Rheumatology (Oxford) 2010;49(6):1203-6
   PubMedGoogle Scholar
• Dagna L, Corti A, Langheim S, et al. Tumor necrosis factor alpha as a master regulator of inflammation in Erdheim-Chester disease: rationale for the treatment of patients with infliximab. J Clin Oncol 2012;30(28):e286-90
   PubMed Web of Science ®Google Scholar
• Stoppacciaro A, Ferrarini M, Salmaggi C, et al. Immunohistochemical evidence of a cytokine and chemokine network in three patients with Erdheim-Chester disease: implications for pathogenesis. Arthritis Rheum 2006;54(12):4018-22
   PubMedGoogle Scholar
• Haroche J, Charlotte F, Arnaud L, et al. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood 2012;120(13):2700-3
   PubMed Web of Science ®Google Scholar
• Blombery P, Wong SQ, Lade S, Prince HM. Erdheim-Chester disease harboring the BRAF V600E mutation. J Clin Oncol 2012;30(32):e331-2
   PubMedGoogle Scholar
• Emile JF, Charlotte F, Amoura Z, Haroche J. BRAF mutations in Erdheim-Chester disease. J Clin Oncol 2013;31(3):398
   PubMed Web of Science ®Google Scholar
• Haroche J, Cohen-Aubart F, Emile JF, et al. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood 2013;121(9):1495-500
   PubMed Web of Science ®Google Scholar
• Heaney ML. Saving orphans: BRAF targeting of histiocytosis. Blood 2013;121(9):1487-8
   PubMedGoogle Scholar
• Suzuki HI, Hosoya N, Miyagawa K, et al. Erdheim-Chester disease: multisystem involvement and management with interferon-alpha. Leuk Res 2010;34(1):e21-4
   Google Scholar
• Luft T, Luetjens P, Hochrein H, et al. IFN-alpha enhances CD40 ligand-mediated activation of immature monocyte-derived dendritic cells. Int Immunol 2002;14(4):367-80
   PubMedGoogle Scholar
• Luft T, Pang KC, Thomas E, et al. Type I IFNs enhance the terminal differentiation of dendritic cells. J Immunol 1998;161(4):1947-53
   PubMed Web of Science ®Google Scholar
• Brown RE. Interferon-alpha therapy, protein kinase C-alpha and Langerhans cell histiocytosis. Med Pediatr Oncol 2003;41(1):63-4
   PubMedGoogle Scholar
• Hervier B, Arnaud L, Charlotte F, et al. Treatment of Erdheim-Chester disease with long-term high-dose interferon-alpha. Semin Arthritis Rheum 2012;41(6):907-13
   PubMed Web of Science ®Google Scholar
• Aouba A, Larousserie F, Le Guern V, et al. Spumous histiocytic oligoarthritis coexisting with systemic Langerhans' cell histiocytosis: case report and literature review. Joint Bone Spine 2009;76(6):701-4
   PubMedGoogle Scholar
• Mascalchi M, Nencini P, Nistri M, et al. Failure of radiation therapy for brain involvement in Erdheim Chester disease. J Neurooncol 2002;59(2):169-72
   PubMed Web of Science ®Google Scholar
• Franco P, Filippi AR, Ciammella P, et al. Polyostotic sclerosing histiocytosis (Erdheim-Chester disease) treated with combined vertebroplasty and radiation therapy. Tumori 2010;96(4):633-6
   PubMedGoogle Scholar
• Miller RC, Villa S, Kamer S, et al. Palliative treatment of Erdheim-Chester disease with radiotherapy: a Rare Cancer Network study. Radiother Oncol 2006;80(3):323-6
   PubMed Web of Science ®Google Scholar
• Haroche J, Arnaud L, Cohen-Aubart F, et al. Erdheim-Chester disease. Rheum Dis Clin North Am 2013;39(2):299-311
   PubMed Web of Science ®Google Scholar
• Gaspar N, Boudou P, Haroche J, et al. High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation for adult histiocytic disorders with central nervous system involvement. Haematologica 2006;91(8):1121-5
   PubMed Web of Science ®Google Scholar
• Mazor RD, Manevich-Mazor M, Shoenfeld Y. Erdheim-Chester disease: a comprehensive review of the literature. Orphanet J Rare Dis 2013;8(1):137
   PubMedGoogle Scholar